Article summary
As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position β not by chasing headlines, but by building a broad, durable intellectual property estate to anchor the next generation of non-hallucinogenic, neuroplasticity-enhancing medicines. The post Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up appeared first on Microdose.
Continue to the original publication for the complete article.